About Terns Pharmaceuticals, Inc.
https://www.ternspharma.comTerns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity.
CEO
Amy L. Burroughs
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 91
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Truist Securities
Buy
HC Wainwright & Co.
Buy
Jefferies
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Oppenheimer
Outperform
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
SOLEUS CAPITAL MANAGEMENT, L.P.
Shares:8.13M
Value:$302.17M
MORGAN STANLEY
Shares:7.59M
Value:$282.16M
ORBIMED ADVISORS LLC
Shares:7.56M
Value:$281.19M
Summary
Showing Top 3 of 153
About Terns Pharmaceuticals, Inc.
https://www.ternspharma.comTerns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $27.72M ▲ | $-24.64M ▼ | 0% | $-0.27 ▼ | $-24.58M ▼ |
| Q2-2025 | $0 | $27.27M ▼ | $-24.09M ▼ | 0% | $-0.26 | $-23.92M ▲ |
| Q1-2025 | $0 | $27.43M ▲ | $-23.91M ▼ | 0% | $-0.26 ▼ | $-27.26M ▼ |
| Q4-2024 | $0 | $25.95M ▲ | $-21.8M ▲ | 0% | $-0.24 ▲ | $-25.73M ▼ |
| Q3-2024 | $0 | $24.94M | $-21.95M | 0% | $-0.28 | $-24.73M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $295.63M ▼ | $301.65M ▼ | $17.59M ▲ | $284.07M ▼ |
| Q2-2025 | $315.44M ▼ | $320.42M ▼ | $15.19M ▲ | $305.23M ▼ |
| Q1-2025 | $334.26M ▼ | $339.31M ▼ | $13.27M ▼ | $326.04M ▼ |
| Q4-2024 | $358.16M ▼ | $363.93M ▼ | $18.06M ▲ | $345.87M ▼ |
| Q3-2024 | $372.78M | $378.23M | $13.76M | $364.47M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-24.64M ▼ | $-19.77M ▼ | $24.5M ▼ | $0 ▼ | $4.73M ▼ | $-19.77M ▼ |
| Q2-2025 | $-24.09M ▼ | $-18.88M ▲ | $25.5M ▲ | $324K ▲ | $6.94M ▲ | $-18.88M ▲ |
| Q1-2025 | $-23.91M ▼ | $-24.45M ▼ | $1.96M ▲ | $74K ▼ | $-22.42M ▲ | $-24.45M ▼ |
| Q4-2024 | $-21.8M ▲ | $-14.58M ▲ | $-94.35M ▼ | $304K ▼ | $-108.7M ▼ | $-14.58M ▲ |
| Q3-2024 | $-21.95M | $-16.45M | $31.75M | $163.29M | $178.64M | $-16.45M |
CEO
Amy L. Burroughs
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 91
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Truist Securities
Buy
HC Wainwright & Co.
Buy
Jefferies
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Oppenheimer
Outperform
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
SOLEUS CAPITAL MANAGEMENT, L.P.
Shares:8.13M
Value:$302.17M
MORGAN STANLEY
Shares:7.59M
Value:$282.16M
ORBIMED ADVISORS LLC
Shares:7.56M
Value:$281.19M
Summary
Showing Top 3 of 153